HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$78.17
0.31 (0.40%)
▲
5d:
+1.66%
30d:
+7.48%
90d:
+26.86%
HOLD
MODERATE Confidence
Analysis Updated: Jul 20, 2026 12:00 AM ET
Earnings: Aug 06, 2026
15d
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HAE trades at premium valuation expecting 4.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: HAE trades at premium valuation expecting 4.8% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$88.50
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$54.95
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $78.17, which is considered extended relative to its 30-day fair value range of $73.67 to $77.29. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.8) compared to its historical average (12.8). At these levels, the market is pricing in 4.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is approaching resistance at $80.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HAE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $86.60 (+10.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is approaching resistance at $80.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HAE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $86.60 (+10.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$73.67 -
$77.29
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.6%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($86.60)
- NEUTRAL: Trading at premium valuation - market expects 4.8% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$73.67 -
$77.29
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$71.81
Resistance Level
$80.00
Current Trend
Strong Uptrend
Technical data as of
Jul 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.77
Wall Street Target
$86.60
(+10.8%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
28.4%
Profit Margin
7.3%
Valuation Premium vs History
+4.8% premium
PE vs Historical
14.8 vs 12.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.8%
(market-implied from PE analysis)
1-Year Target
$81.92
(+5%)
2-Year Target
$85.85
(+10%)
3-Year Target
$89.98
(+15%)
3-Yr Target (if PE normalizes)
(PE: 15→13)
PE COMPRESSION
$77.96
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.9, Growth: 7.0%)
$135.96
(+74%)
Base:
(SPY PE: 14.8, Growth: 7.0%)
$95.87
(+23%)
Bear:
(PE: 12.6, Growth: 7.0%)
$81.49
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 37.98 | Current EPS (TTM): $2.05
Bull Case
$171.29
(+119%)
Analyst growth 100.0%, PE expands to 41.8
Base Case
$155.72
(+99%)
Market implied 100.0%, PE stable at 38.0
Bear Case
$52.94
(-32%)
Severe decline -20.0%, PE contracts to 32.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 21, 2026 4:18 AM ET
Data refreshes hourly during market hours. Next update: 5:18 AM
Data refreshes hourly during market hours. Next update: 5:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$86 | 65 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 60 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 68 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$238 | 67 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
